Eric Joseph
Stock Analyst at JP Morgan
(2.06)
# 2,997
Out of 5,067 analysts
125
Total ratings
38.82%
Success rate
-5.56%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $32.03 | +52.98% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $23.62 | +94.75% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $65.59 | -2.42% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.03 | +131.02% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.79 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $6.63 | +5.58% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $79.83 | -16.07% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.30 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.57 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $17.15 | +74.93% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $6.12 | +128.76% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $73.66 | -3.61% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $28.51 | +33.29% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $3.33 | +590.69% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $7.46 | +127.88% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $8.17 | +157.04% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $13.65 | -26.74% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.01 | +1,385.15% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.46 | +143.90% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $4.33 | +130.95% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $15.76 | -30.20% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $54.36 | -24.58% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $22.72 | +340.14% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.52 | +861.54% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.99 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $28.04 | -60.77% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $13.10 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $5.56 | +2,058.27% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $9.52 | +3,052.92% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.76 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.24 | +625.81% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.59 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $3.85 | +990.91% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $3.32 | +291.57% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.42 | +2,540.42% | 3 | Nov 14, 2018 |
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $32.03
Upside: +52.98%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $23.62
Upside: +94.75%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $65.59
Upside: -2.42%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.03
Upside: +131.02%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.79
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $6.63
Upside: +5.58%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $79.83
Upside: -16.07%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.30
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.57
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $17.15
Upside: +74.93%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $6.12
Upside: +128.76%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $73.66
Upside: -3.61%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $28.51
Upside: +33.29%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $3.33
Upside: +590.69%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $7.46
Upside: +127.88%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $8.17
Upside: +157.04%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $13.65
Upside: -26.74%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.01
Upside: +1,385.15%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.46
Upside: +143.90%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $4.33
Upside: +130.95%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $15.76
Upside: -30.20%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $54.36
Upside: -24.58%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $22.72
Upside: +340.14%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.52
Upside: +861.54%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $2.99
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $28.04
Upside: -60.77%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $13.10
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $5.56
Upside: +2,058.27%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $9.52
Upside: +3,052.92%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $9.76
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.24
Upside: +625.81%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.59
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $3.85
Upside: +990.91%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $3.32
Upside: +291.57%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.42
Upside: +2,540.42%